GlassScriptPhysician profile
David Kevin White
NPI 1982673786
$17,669.82
in general payments reported to CMS, 2019-2025
61 companies · $1,390 in 2025
The $1,390 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,933 · 2020: $2,931 · 2021: $3,106 · 2022: $2,548 · 2023: $2,620 · 2024: $2,142 · 2025: $1,390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,151.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,093.13 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,754.31 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amarin Pharma, INC. | $1,478.09 | 2019-2022 | |
| Glaxosmithkline, LLC. | $1,475.54 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,304.14 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $1,086.16 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $961.48 | 2019-2024 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $873.07 | 2019-2025 | |
| Amgen INC. | $816.11 | 2019-2024 | Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $614.93 | 2019-2022 | |
| Dexcom, INC. | $502.01 | 2022-2024 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $430.06 | 2019-2024 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $339.95 | 2019-2025 | |
| Antares Pharma, INC. | $305.45 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Bayer Healthcare Pharmaceuticals INC. | $299.31 | 2021-2025 |
Show all 61 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David White listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.